Group 1 - The U.S. Food and Drug Administration has approved a higher-dose version of Biogen's drug for a rare genetic disorder, which may provide patients with a more effective treatment option [1] - Biogen's drug targets a condition that causes progressive muscle weakness, indicating a significant advancement in treatment options for affected patients [1] Group 2 - Italian coffee maker Lavazza reported an increase in annual revenue and profit, despite facing challenges from high coffee bean prices and weaker global demand [2] - The company's ability to maintain profitability amidst rising costs and declining demand highlights its resilience in the coffee industry [2]